Volume 28, Number 1—January 2022
Research
Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017‒2020
Marta Bes
, Maria I. Costafreda, Mar Riveiro-Barciela, Maria Piron, Angie Rico, Josep Quer, Lluis Puig, and Silvia Sauleda
, Maria I. Costafreda, Mar Riveiro-Barciela, Maria Piron, Angie Rico, Josep Quer, Lluis Puig, and Silvia Sauleda
Table 3
Follow-up of HEV RNA positive blood donors, Catalonia, Spain*
| Characteristic | Baseline | 1-month follow-up | 2-month follow-up | 6-month follow-up | >1 year follow-up |
|---|---|---|---|---|---|
| No. persons |
151 |
127 |
29 |
38 |
20 |
| Interval between tests, d (range) |
NA |
20 (8–61) |
53 (36–90) |
242 (110–364) |
534 (371–945) |
| HEV RNA positive | 151 (100.0) | 80 (63.0) | 7 (24.1) | 0 | 0 |
| HEV IgM positive | 63 (42.0) | 95 (74.8) | 29 (100.0) | 30 (78.9) | 12 (60.0) |
| HEV IgG positive |
45 (43.0) |
99 (78.0) |
28 (96.6) |
38 (100.0) |
18 (90.0) |
| Biochemical parameters | |||||
| Bilirubin >1.1 mg/dL | 4 (2.6) | 4 (3.1) | 1 (3.4) | NA | NA |
| AST >80 U/L | 10 (6.6) | 6 (4.7) | 0 | NA | NA |
| ALT >80 U/L | 15 (9.9) | 12 (10.2) | 0 | NA | NA |
| γ-glutamyltransferase > 55 U/L | 24 (15.9) | 18 (15.7) | 3 (10.3) | NA |
*Values are no. (%) unless indicated otherwise. ALT, alanine aminotransferase; AST, aspartate aminotransferase; HEV, hepatitis E virus; NA, not applicable.
Page created: October 13, 2021
Page updated: December 20, 2021
Page reviewed: December 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.